141 related articles for article (PubMed ID: 6197164)
21. Factors involved in the plasminogen activation system in human breast tumours.
Damjanovich L; Turzó C; Adány R
Thromb Haemost; 1994 Jun; 71(6):684-91. PubMed ID: 7974332
[TBL] [Abstract][Full Text] [Related]
22. Antibody immunoglobulin G (IgG) against human prostatic specific antigen (PSA) as a carrier protein for chemotherapeutic drugs to human prostate tumors: Part 1. A double immunofluorescence analysis.
Sinha AA; Sackrison JL; DeLeon OF; Wilson MJ; Gleason DF
Anat Rec; 1996 Aug; 245(4):652-61. PubMed ID: 8837723
[TBL] [Abstract][Full Text] [Related]
23. Effects of N-(4-hydroxyphenyl) retinamide on urokinase-type plasminogen activator and plasminogen activator inhibitor-1 in prostate adenocarcinoma cell lines.
Tanabe T
Hiroshima J Med Sci; 2000 Mar; 49(1):67-72. PubMed ID: 10824459
[TBL] [Abstract][Full Text] [Related]
24. Both the cytosols and detergent extracts of breast cancer tissues are suited to evaluate the prognostic impact of the urokinase-type plasminogen activator and its inhibitor, plasminogen activator inhibitor type 1.
Jänicke F; Pache L; Schmitt M; Ulm K; Thomssen C; Prechtl A; Graeff H
Cancer Res; 1994 May; 54(10):2527-30. PubMed ID: 8168072
[TBL] [Abstract][Full Text] [Related]
25. Secretion of matrix metalloproteinases and their inhibitors (tissue inhibitor of metalloproteinases) by human prostate in explant cultures: reduced tissue inhibitor of metalloproteinase secretion by malignant tissues.
Lokeshwar BL; Selzer MG; Block NL; Gunja-Smith Z
Cancer Res; 1993 Oct; 53(19):4493-8. PubMed ID: 7691397
[TBL] [Abstract][Full Text] [Related]
26. Immunohistochemical staining of urokinase plasminogen activator-like and urokinase plasminogen activator receptor-like proteins in the urinary tract of healthy dogs.
Bailey TR; Paulsen DB; Sehgal I; Hosgood G
Am J Vet Res; 2006 Sep; 67(9):1628-34. PubMed ID: 16948613
[TBL] [Abstract][Full Text] [Related]
27. Fibrin formation on vessel walls in hyperplastic and malignant prostate tissue.
Wojtukiewicz MZ; Zacharski LR; Memoli VA; Kisiel W; Kudryk BJ; Moritz TE; Rousseau SM; Stump DC
Cancer; 1991 Mar; 67(5):1377-83. PubMed ID: 1703919
[TBL] [Abstract][Full Text] [Related]
28. Comparison of the relative fibrinogenolytic, fibrinolytic and thrombolytic properties of tissue plasminogen activator and urokinase in vitro.
Matsuo O; Rijken DC; Collen D
Thromb Haemost; 1981 Jun; 45(3):225-9. PubMed ID: 7025339
[TBL] [Abstract][Full Text] [Related]
29. Urokinase plasminogen activator, uPa receptor, and its inhibitor in vernal keratoconjunctivitis.
Leonardi A; Brun P; Sartori MT; Cortivo R; Dedominicis C; Saggiorato G; Abatangelo G; Secchi AG
Invest Ophthalmol Vis Sci; 2005 Apr; 46(4):1364-70. PubMed ID: 15790903
[TBL] [Abstract][Full Text] [Related]
30. Human hepatoma cell line plasminogen activator.
Levin EG; Fair DS; Loskutoff DJ
J Lab Clin Med; 1983 Oct; 102(4):500-8. PubMed ID: 6311924
[TBL] [Abstract][Full Text] [Related]
31. Tissue plasminogen activator activity in prostatic cancer.
Köller A; Kirchheimer J; Pflüger H; Binder BR
Eur Urol; 1984; 10(6):389-94. PubMed ID: 6085049
[TBL] [Abstract][Full Text] [Related]
32. Human urokinase receptor concentration in malignant and benign breast tumors by in vitro quantitative autoradiography: comparison with urokinase levels.
Del Vecchio S; Stoppelli MP; Carriero MV; Fonti R; Massa O; Li PY; Botti G; Cerra M; D'Aiuto G; Esposito G
Cancer Res; 1993 Jul; 53(13):3198-206. PubMed ID: 7686450
[TBL] [Abstract][Full Text] [Related]
33. Enhancement of the expression of urokinase-type plasminogen activator from PC-3 human prostate cancer cells by thrombin.
Yoshida E; Verrusio EN; Mihara H; Oh D; Kwaan HC
Cancer Res; 1994 Jun; 54(12):3300-4. PubMed ID: 8205553
[TBL] [Abstract][Full Text] [Related]
34. Characteristics of nonmalignant and malignant human prostate in organ culture.
Varani J; Dame MK; Wojno K; Schuger L; Johnson KJ
Lab Invest; 1999 Jun; 79(6):723-31. PubMed ID: 10378515
[TBL] [Abstract][Full Text] [Related]
35. [The role of urokinase-type plasminogen activator in the pathogenesis of pemphigus].
Nie Z; Liu R; Ye Q
Zhonghua Yi Xue Za Zhi; 1997 Oct; 77(10):771-3. PubMed ID: 9772525
[TBL] [Abstract][Full Text] [Related]
36. In vitro plasminogen activator activity in human brain tumors.
Tucker WS; Kirsch WM; Martinez-Hernandez A; Fink LM
Cancer Res; 1978 Feb; 38(2):297-302. PubMed ID: 620402
[TBL] [Abstract][Full Text] [Related]
37. Expression of urokinase-type plasminogen activator, urokinase-type plasminogen activator receptor and plasminogen activator inhibitors in patients with renal cell carcinoma: correlation with tumor associated macrophage and prognosis.
Ohba K; Miyata Y; Kanda S; Koga S; Hayashi T; Kanetake H
J Urol; 2005 Aug; 174(2):461-5. PubMed ID: 16006865
[TBL] [Abstract][Full Text] [Related]
38. Abnormal levels of urokinase plasminogen activator protein and tissue plasminogen activator activity in human aortic aneurysms.
Falkenberg M; Holmdahl L; Tjärnström J; Risberg B
Eur J Surg; 2001 Jan; 167(1):10-4. PubMed ID: 11213813
[TBL] [Abstract][Full Text] [Related]
39. Clinical relevance of urokinase plasminogen activator, its receptor, and its inhibitor in patients with renal cell carcinoma.
Hofmann R; Lehmer A; Buresch M; Hartung R; Ulm K
Cancer; 1996 Aug; 78(3):487-92. PubMed ID: 8697395
[TBL] [Abstract][Full Text] [Related]
40. Hormone regulation of human prostate in organ culture.
Nevalainen MT; Härkönen PL; Valve EM; Ping W; Nurmi M; Martikainen PM
Cancer Res; 1993 Nov; 53(21):5199-207. PubMed ID: 7693334
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
